Why Submit to Blood
- In continuous publication since 1946, Blood is THE #1 cited journal in the field of hematology.
- With an average of 443 references daily, Blood is the best vehicle for reaching the hematology realm.
- Blood editors are experts within the field of hematology and manuscripts are reviewed by prominent specialists.
|"I publish in Blood because of the impact the journal has on influencing practice and subsequent research, and because I know the findings from my research will be disseminated quickly."
Mikkael Sekeres MD, MS, Professor of Medicine, Cleveland Clinic
||How to Get Published in a Peer-Reviewed Journal: Presentation
Bob Löwenberg, MD, PhD
Erasmus University Medical Center
Rotterdam, the Netherlands
Brad Kahl, MD
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., … Wagner-Johnston, N. D. (2014). A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/ refractory mantle cell lymphoma (MCL).
Blood, 123(22), 3398–3405.
|Author Resources||Tweets by BloodJournal|
|Submit to Blood|